Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliograf¿a
[1]
Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology. 1974;66:916-22.
[2]
Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-7.
[3]
Controlled trial of azatioprine in Crohn's disease. Lancet. 1971;2:1273-6.
[4]
Controlled trial of azathioprine in Crohn´s disease. Lancet. 1971;2:944-7.
[5]
Azatioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000:CD000545.
[6]
Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 1995;123:132-42.
[7]
Azathioprine for maintaining remission of Crohn´s disease. Cochrane Database Syst Rev. 2000:CD000067.
[8]
Azathioprine and mesalamine for prevention of relapse after conservative therapy for Crohn's disease. Gastroenterology. 2004;127:730-40.
[9]
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
[10]
Long-term follow up of patients with Crohn's disease treated with azatioprine or 6 mercaptopurine. Lancet. 1996;347:215-9.
[11]
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 1999;117:527-35.
[12]
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-6.
[13]
Hepatotoxicity of mercaptopurine. Arch Intern Med. 1968;122:54-8.
[14]
Increased incidence of azathioprine induced pancreatitis in Crohn's disease compared wih other diseases. Aliment Pharmacol Ther. 2004;20:843-50.
[15]
6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39:401-6.
[16]
Pharmacogenetics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-13.
[17]
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-52.
[18]
The outcome of pregnancy following renal transplantation.The experience of a single center. Transplantation. 1992;54:429-32.
[19]
Vertical development of the secondary palate in hamster embryos following exposure to 6-mercaptopurine. Teratology. 1988;37:591-7.
[20]
The safety of 6-mercaptopurine for chidbearing patientswith inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9-17.
[21]
Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000;95:684-8.
[22]
A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-35.
[23]
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
[24]
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-9.
[25]
The effects of infliximab maintenance therapy on health-related quality of life. Am J gastroenterol. 2003;98:2232-8.
[26]
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.
[27]
Remission in patines with Crohn's disease is associated with improvement in employment and quality of life and dicrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-6.
[28]
Predictors of response to infliximab in patients with Crohn´s disease. Gastroenterology. 2002;123:707-13.
[29]
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
[30]
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
[31]
Long-term treatment of rectovaginal fistulas in Crohn´s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2:912-20.
[32]
Infliximab in Crohn´s disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-77.
[33]
Clinical experience with infliximab therapyin 100 patients with Crohn´s disease. Am J gastroenterol. 2000;95:3490-7.
[34]
The presence of intestinal strictures is associated with poorer responses for active or fistulizing Crohn's disease. Am J Gastroenterol. 1999;94:2676.
[35]
Complete bowel obstruction following initial response to infliximab therapy for Crohn´s disease: a series of a newly described complication. Gastroenterology. 2000;118:A569.
[36]
Long term follow up of patients treated with infliximab (anti-TNFalfa antibody) in clinical trials [abstract]. Gastroenterology. 2000;18:A566.
[37]
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockolm County. Gut. 2004;53:849-53.
[38]
The safety profile of infliximab in patients with Crohn´s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
[39]
The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24.
[40]
Influence of inmunogenicity on the long-term efficacy of infliximab in Crohn´s disease. N Engl J Med. 2003;348:601-8.
[41]
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn´s disease. Clin Gastroenterol Hepatol. 2004;2:542-53.
[42]
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlles trial. Gastroenterology. 2003;124:917-24.
[43]
Autoinmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenteroloy. 2003;125:32-9.
[44]
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
[45]
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-24.
[46]
Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut. 2005;54:732-3.
[47]
Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther. 2001;15:1101-8.
[48]
Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13 Supl 4:16.
[49]
Safety of biologic therapies--an update. J Rheumatol Supl. 2005;74:8-12.
[50]
Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101:295-300.
[51]
Molecular therapeutics: methotrexate and its mechanism of actino. Arthritis Rheum. 1996;39:1951-60.
[52]
The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donors and spermidae. Arthritis Rheum. 1990;33:954-8.
[53]
Immunosuppresive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322-8.
[54]
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-6.
[55]
Methotrexate for the treatment of refractory Crohn´s disease. Aliment Pharmacol Ther. 1996;10:309-14.
[56]
Efficacy of parenteral methotrexate in refractory Crohn´s disease. Alimnt Pharmacol Ther. 2001;15:35-44.
[57]
Methotrexate for the treatment of Crohn´s disease. N Engl J Med. 1995;332:292-7.
[58]
Low-dose oral methotrexate in refractory bowel disease. Dig Dis Sci. 1993;38:1851-6.
[59]
Methotrexate in chronic active Crohn´s disease: a double-blind, randomised Israeli multicenter trial. Am J Gastroenterol. 1997; 92:2203-9.
[60]
A comparison of methotrexate with placebo for the maintenance of remission in Crohn´s disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342:1627-32.
[61]
Methotrexate in Crohn´s disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-4.
[62]
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-6.
[63]
A placebo-controlled, doble-blind, randomised trialk of cyclosporine therapy in active chronic Crohn´s disease. N Engl J Med. 1989;321:845-50.
[64]
European trial of cyclosporine in chronic active Crohn´s disease. A 12-month study. Gastroenteroloy. 1995;109:774-82.
[65]
Cyclosporine Study Group of Great Britain and Ireland. Oral cyclosporine for chronic active Crohn´s disease: a multicentre controlles trial. Eur J Gastroenterol Hepatol. 1994;6:499.
[66]
Low-dose cyclosporine for the treatment of Crohn´s disease. The Canadian Crohn´s relapse prevention trial investigators. N Engl J Med. 1994;330:1846-51.
[67]
Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93:442-8.
[68]
Rapid closure of Crohn´s disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol. 1993;88:646-9.
[69]
Is ther any value in using cyclosporine in the treatment of Crohn´s disease-to use or not to use? Inflamm Bowel Dis. 1995;1:340.
[70]
A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:48.
[71]
Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997;92:876-9.
[72]
Steroid-unresponsive acute attacks of inflammatory bowel disease: inmunomodulation by tacrolimus (FK-506). Am J Gastroenterol. 1998;93:1860-6.
[73]
Mycophenolate mofetil for Crohn´s disease? Lancet. 1999;354:3-4.
[74]
Mycophenolate mofetil in patients with Crohn´s disease. Am J Gastroenterol. 1998;93:2529-32.
[75]
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut. 1999;44:625-8.
[76]
Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171-6.
[77]
A randomized, double-blind, placebo-controlled trial of the human anti TNF alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease [abstract]. Gastroenterology. 2004;127:332.
[78]
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerances to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-9.
[79]
Safety and efficacy of adalimumab (D2E7) in Crohn´s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75-9.
[80]
CDP571, a humanized monoclonal antibody to tumour necrosis factor alpha for moderate to severe Crohn´s disease: a randomized, double blind, placebo controlled trial. Gut. 2004;53:1485-93.
[81]
A randomised, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005;21:373-84.
[82]
Intravenous CDP870, a PEGylated Fab'fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn´s disease: a exploratory study. Aliment Pharmacol Ther. 2004;20:1337-46.
[83]
Etanercept in the treatment of active refractory Crohn´s disease: a single-center pilot trial. Am J Gastroenterol. 2001;96:2564-8.
[84]
Etanercept for active Crohn´s disease: a randomised, double-blin, placebo-controlled trial. Gastroenterology. 2001;121:1088-94.
[85]
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomised, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185-92.
[86]
Anti-interleukin-12 antibody for active Crohn´s disease. N Engl J Med. 2004;351:2069-79.
[87]
Fontilizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn´s disease [abstract]. Gastroenterology. 2004;127:332.
[88]
Multiple doses of intravenous interleuki 10 in steroid-refractory Crohn´s disease. Crohn's disease study group. Gastroenterology. 1997;113:383-9.
[89]
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn´s disease. Crohn´s disease IL-10 Cooperative Group. Gastroenterology. 2000;199:1461-72.
[90]
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn´s disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology. 2000;119:1473-82.
[91]
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn´s disease. Gastroenterology. 1999;117:58-64.
[92]
Antisense-oligonucleotide therapy. N Engl J Med. 1996;334:316-8.
[93]
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn´s disease. Gastroenterology. 2001:120:1339-46.
[94]
Double-blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn´s disease. Gut. 2002;51:30-6.
[95]
A randomized Placebo-Controlled Trial of a Humanized Monoclonal Antibody to alpha4integrin in Active Crohn´s Disease. Gastroenterology. 2001;121:268-74.
[96]
Natalizumab for active Crohn´s disease. N Engl J Med. 2003;348:24-32.
[97]
A preliminary study of growth hormone therapy for Crohn´s disease. N Engl J Med. 2000;342:1633-7.
[98]
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478-80.
[99]
An Open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther. 2005;21:391-400.
[100]
Detection of Mycobacterium avium subspecies paratuberculosis in Crohn´s disease tissues by in situ hybridisation. Am J Gastroenterol. 2001;96:1529-35.
[101]
Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn´s disease. Dig Dis Sci. 1999;44:1202-7.
[102]
Culture of mycobacterium subspecies paratuberculosis from the blood of patients with Crohn´s disease. Lancet. 2004;364:1039-44.
[103]
A meta-analysis of antimycobacterial therapy for Crohn´s disease. Am J gastroenterol. 2000;95:725-9.
[104]
Controlled trial of antimycobacterial therapy in Crohn´s disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36:449-53.
[105]
Antimycobacterial therapy in Crohn´s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994;89:513-8.
[106]
Trichuris suis therapy in Crohn's disease. Gut. 2005;54:87-90.
